Isis Pharmaceuticals CEO Dr. Stanley Crooke

1 00:00:06,910 --> 00:00:10,429 it for today's filing pacing let's not forget that the work actually some 2 00:00:10,429 --> 00:00:11,050 stocks that 3 00:00:11,050 --> 00:00:15,179 rallied this session stocks like kramer faith ices form a suitable was climbed 4 00:00:15,179 --> 00:00:19,590 six dollars in city since 10.72 percent when news about major partnership with 5 00:00:19,590 --> 00:00:20,698 changing to develop 6 00:00:20,699 --> 00:00:24,539 drugs for 18 use disorders affecting the gastrointestinal tract 7 00:00:24,539 --> 00:00:28,279 change a possibly pay as much as $835 million dollars over time 8 00:00:28,279 --> 00:00:32,028 i'd taking any potential role isn't a cap always maintain 9 00:00:32,029 --> 00:00:35,340 ice is a trip to come because there are so many shots on goal 34 different 10 00:00:35,340 --> 00:00:36,809 development programs is pipeline 11 00:00:36,809 --> 00:00:40,468 today's news really brings home that point because before this morning 12 00:00:40,469 --> 00:00:44,420 frankly I don't allow workers coming in every member in the GI tract on the J 13 00:00:44,420 --> 00:00:47,570 changes so excited about this is so many different opportunities 14 00:00:47,570 --> 00:00:50,950 it's hard to keep track for those you don't remember ice is supplying you're 15 00:00:50,950 --> 00:00:51,539 in the field 16 00:00:51,539 --> 00:00:55,690 80 cents technology medical speak for therapies that work by binding to be are 17 00:00:55,690 --> 00:00:57,038 in a in person sells 18 00:00:57,039 --> 00:01:00,629 live in the company's drugs to basically control the expression to be given 19 00:01:00,629 --> 00:01:01,788 individuals jeans 20 00:01:01,789 --> 00:01:06,670 terrific way to treat a broad various nasty inherited genetic disorders 21 00:01:06,670 --> 00:01:10,110 we just bought ice is CEO back in December Ted less than three weeks ago 22 00:01:10,110 --> 00:01:12,830 I'd burn entire segment to the company's revolutionary 23 00:01:12,830 --> 00:01:17,408 anti-clotting drug FX I 1 %uh many potential blockbusters in the company's 24 00:01:17,409 --> 00:01:17,909 pipeline 25 00:01:17,909 --> 00:01:21,780 which also includes ices of Phase three treatment for TTR and worry 26 00:01:21,780 --> 00:01:25,530 dice its phase 3 therapy for spinal muscular atrophy 27 00:01:25,530 --> 00:01:28,680 which is the leading cause of him tell death worldwide not to mention the catch 28 00:01:28,680 --> 00:01:31,720 a trip to come is developing for its own diabetes formulations it 29 00:01:31,720 --> 00:01:35,280 now ices rallied nearly 55 percent this year today's move tells me 30 00:01:35,280 --> 00:01:38,290 this innovation could have a lot more room to run don't think it for me let's 31 00:01:38,290 --> 00:01:41,409 check in with doctor stanley quote the Founder Chairman CEO of my sis 32 00:01:41,409 --> 00:01:44,510 hear more about this partnership will change and what it means for 33 00:01:44,510 --> 00:01:47,980 the doctor cock welcome back Jul its greatest 34 00:01:47,980 --> 00:01:51,650 way to start the new year okay what I I did not know that 35 00:01:51,650 --> 00:01:54,850 that you were working on autoimmune disorders to the gastrointestinal tract 36 00:01:54,850 --> 00:01:59,600 what J&J's Janssen division see that they think they can commercialize you 37 00:01:59,600 --> 00:02:05,960 well an assist technology is versatile and it's and it's efficient and 38 00:02:05,960 --> 00:02:09,399 highly specific and so it's an incredible tool 39 00:02:09,399 --> 00:02:13,470 the to add to the efficiency and drug discovery 40 00:02:13,470 --> 00:02:16,700 of course we do have experience in the GI tract 41 00:02:16,700 --> 00:02:20,220 some years ago with the first generation antisense drug 42 00:02:20,220 --> 00:02:24,150 so we do have GI experience and what's really exciting 43 00:02:24,150 --> 00:02:27,400 to us about this collaboration is 44 00:02:27,400 --> 00:02:30,940 it it it it expands the borders have the technology 45 00:02:30,940 --> 00:02:35,470 once again because this is focused now on oral administration 46 00:02:35,470 --> 00:02:39,050 for local treatment gastrointestinal diseases 47 00:02:39,050 --> 00:02:43,220 and so that's a space that's new for the technology but its 48 00:02:43,220 --> 00:02:47,239 adjacent to areas that we've worked before so we have high confidence it can 49 00:02:47,239 --> 00:02:47,970 work 50 00:02:47,970 --> 00:02:53,489 and once again expands the breadth utility in the technology I think that's 51 00:02:53,489 --> 00:02:54,090 the thing 52 00:02:54,090 --> 00:02:57,830 that should get people most excited one more 53 00:02:57,830 --> 00:03:01,600 not on the belt of all the different opportunities that we have 54 00:03:01,600 --> 00:03:05,220 to take advantage of with this technology what specific illnesses are 55 00:03:05,220 --> 00:03:08,200 we speaking up when we speak of gastrointestinal tract Hills 56 00:03:08,200 --> 00:03:13,190 well these are is often inflammatory diseases like Crohn's and ulcerative 57 00:03:13,190 --> 00:03:17,060 colitis and then their diseases like your double ballot syndrome 58 00:03:17,060 --> 00:03:21,370 and then they're all the inflammatory disorders that that relate to the immune 59 00:03:21,370 --> 00:03:23,239 function so the GI tract 60 00:03:23,239 --> 00:03:27,850 so there's a very large consolation to diseases that are primarily manifested 61 00:03:27,850 --> 00:03:28,590 in the gut 62 00:03:28,590 --> 00:03:33,329 a and and n new treatments are needed desperately 63 00:03:33,329 --> 00:03:34,730 J&J 64 00:03:34,730 --> 00:03:39,870 of course brings experience in that space with Remicade in all the other 65 00:03:39,870 --> 00:03:41,659 work that they have done over the years 66 00:03:41,659 --> 00:03:45,489 so there the ideal partner that we would choose to 67 00:03:45,489 --> 00:03:49,940 to do this next step in the technology I noticed it too close a 68 00:03:49,940 --> 00:03:53,940 a doctor that you appointed Sarah Boyce's chief business 69 00:03:53,940 --> 00:03:57,670 officer she used to be it Biden abortus I'll exxon for slabs 70 00:03:57,670 --> 00:04:00,970 are you in a different phase now with my sis are you in the face for your 71 00:04:00,970 --> 00:04:03,340 commercializing not taught what's in the lab 72 00:04:03,340 --> 00:04:06,680 well we r evolving 73 00:04:06,680 --> 00:04:11,290 now and and in that evolution to things that we want to accomplish 74 00:04:11,290 --> 00:04:15,459 the first is there's there is a group of drugs in particular the 75 00:04:15,459 --> 00:04:19,070 the drugs to constitute or lipid franchise now 76 00:04:19,070 --> 00:04:23,479 a pushy three rx able they are actually an engine put like three rx 77 00:04:23,479 --> 00:04:26,740 all three unique forming a true franchise 78 00:04:26,740 --> 00:04:29,880 and all having a 79 00:04:29,880 --> 00:04:33,789 relatively rare disease opportunity to begin with and then a much broader 80 00:04:33,789 --> 00:04:34,760 opportunity 81 00:04:34,760 --> 00:04:39,760 so those trucks were keeping a and we're in phase 3 with a pushy three in phase 2 82 00:04:39,760 --> 00:04:40,960 with a belay and 83 00:04:40,960 --> 00:04:44,049 about to go down face to with and you put like three 84 00:04:44,050 --> 00:04:49,639 and and so well we're certainly keeping in two phase 3 and 85 00:04:49,639 --> 00:04:53,340 and beam a commercialized them so ourselves our partner them at a later 86 00:04:53,340 --> 00:04:54,160 date 87 00:04:54,160 --> 00:04:57,539 the goal there is to retain much more control 88 00:04:57,539 --> 00:05:02,000 and to and two course retain a much bigger piece in the Bakken 89 00:05:02,000 --> 00:05:05,110 so sharer brings 90 00:05:05,110 --> 00:05:08,680 you know all this successful business experience to 91 00:05:08,680 --> 00:05:12,310 to contribute to the decision making that entices 92 00:05:12,310 --> 00:05:16,880 from a business perspective and that's very important what should be managing 93 00:05:16,880 --> 00:05:20,750 to a number of functions that use report directly to lynn partial 94 00:05:20,750 --> 00:05:24,169 and now they'll report to her to didn't 95 00:05:24,169 --> 00:05:28,630 tend to lynn and tomorrow we'll announce the appointment AFP also 96 00:05:28,630 --> 00:05:32,969 propolis who will will will become CEO 97 00:05:32,970 --> 00:05:36,479 other newly formed subsidiary we call axiom 98 00:05:36,479 --> 00:05:41,820 and that that subsidiary is responsible or will be responsible for the late 99 00:05:41,820 --> 00:05:44,530 development commercialization number lipid franchise 100 00:05:44,530 --> 00:05:46,710 so these are big step for us 101 00:05:46,710 --> 00:05:51,349 I'll and yet they are steps that are consistent with the designer the company 102 00:05:51,349 --> 00:05:55,628 which is much more consortium sort of configuration rather than 103 00:05:55,629 --> 00:06:00,719 the this or a preamble fully integrated pharmaceutical company configuration 104 00:06:00,719 --> 00:06:03,759 and absolutely assures that the core a vice is 105 00:06:03,759 --> 00:06:08,589 state focus on where the real leverage years which is basic science 106 00:06:08,589 --> 00:06:13,520 technology development drug discovery and early development well doctor 107 00:06:13,520 --> 00:06:16,580 crop once again I mean this is breathtaking new smart stock up 10 108 00:06:16,580 --> 00:06:19,389 percent in one day and one the worst days you had a long time 109 00:06:19,389 --> 00:06:23,490 thank you so much for coming on a mad money well appreciated 110 00:06:23,490 --> 00:06:27,599 it's great to be back get Stanley cook cookies the Chairman CEO 111 00:06:27,599 --> 00:06:30,990 up ices pharmaceuticals nicest that would have been up even more 112 00:06:30,990 --> 00:06:33,319 the market one so hard name on his back

No comments:

Post a Comment